Longleaf Partners Global Fund Q3 2026 Portfolio Review
Longleaf Partners Global Fund’s Q3 2026 review cited strong results from Regeneron, with Dupixent growth exceeding expectations, and noted Abbott’s earlier earnings miss amid its integration of Exact Sciences and industry turmoil. People Inc. and MGM Resorts detracted during the quarter.
Why it matters — The excerpt does not mention Albertsons, so it provides no company-specific information for ACI watchers.